Erschienen in:
07.12.2021 | COVID-19 | Original Paper
Zur Zeit gratis
Clinical course and risk factors for severe COVID-19 among Italian patients with cystic fibrosis: a study within the Italian Cystic Fibrosis Society
verfasst von:
Carla Colombo, Marco Cipolli, Valeria Daccò, Paola Medino, Federico Alghisi, Maura Ambroni, Raffaele Badolato, Fiorella Battistini, Elisabetta Bignamini, Rosaria Casciaro, Fabiana Ciciriello, Mirella Collura, Isabella Comello, Michela Francalanci, Francesca Ficili, Anna Folino, Salvatore Leonardi, Giuseppina Leonetti, Maria Cristina Lucanto, Francesca Lucca, Massimo Maschio, Valeria Mencarini, Barbara Messore, Giovanna Pisi, Giovanna Pizzamiglio, Piercarlo Poli, Valeria Raia, Luca Riberi, Mirco Ros, Novella Rotolo, Angela Sepe, Giovanni Taccetti, Pamela Vitullo, Gianfranco Alicandro
Erschienen in:
Infection
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To describe the clinical course of COVID-19 in patients with cystic fibrosis (CF) and to identify risk factors for severe COVID-19.
Methods
We conducted a prospective study within the Italian CF Society. CF centers collected baseline and follow-up data of patients with virologically confirmed SARS-CoV-2 infection between March 2020 and June 2021. Odds ratios (ORs) for severe SARS-CoV-2 (as defined by hospital admission) were estimated by logistic regression models.
Results
The study included 236 patients with positive molecular test for SARS-CoV-2. Six patients died, 43 patients were admitted to hospital, 4 admitted to intensive care unit. Pancreatic insufficiency was associated with increased risk of severe COVID-19 (OR 4.04, 95% CI 1.52; 10.8). After adjusting for age and pancreatic insufficiency, forced expiratory volume in one second (FEVp) < 40% (OR 4.54, 95% CI 1.56; 13.2), oxygen therapy (OR 12.3, 95% CI 2.91–51.7), underweight (OR 2.92, 95% CI 1.12; 7.57), organ transplantation (OR 7.31, 95% CI 2.59; 20.7), diabetes (OR 2.67, 95% CI 1.23; 5.80) and liver disease (OR 3.67, 95% CI 1.77; 7.59) were associated with increased risk of severe COVID-19, while use of dornase alfa was associated with a reduced risk (OR 0.34, 95% CI 0.13–0.88). No significant changes were observed in FEVp from baseline to a median follow-up of 2 months (median difference: 0, interquartile range: − 4; 5, P = 0.62).
Conclusion
Clinical features indicative of severe form of CF are associated with increased risk of COVID-19 hospitalization. SARS-CoV-2 infected patients do not experience a deterioration of respiratory function.